Chronic urticaria in children under 15 years of age: Clinical experience beyond the clinical trials
article
OA: closed
CC0
Abstract
BACKGROUND/OBJECTIVES: The aim of the study was to describe the clinical characteristics, management, and outcome of a series of children with chronic urticaria (CU). METHODS: We retrospectively studied children aged <15 years diagnosed with CU in a tertiary teaching hospital in Palma de Mallorca, Spain, between January 2014 and March 2019. CU was defined as persistence of symptoms of wheals, with or without angioedema, for >6 weeks. RESULTS: Twenty-nine patients (17 girls, mean age 8 years) were included. Family history of atopy was found in 31% of the cases. In 41.3% of patients, episodes of CU were associated with angioedema. Physical triggers were found in 34.5% of the cases. Most episodes of CU were successfully managed with the recommended (60.7%) or double the recommended dose (17.2%) of H1-antihistamines. Quadruple the recommended dose of H1 antihistamines was used in six patients, five of whom were finally treated with off-label omalizumab. Treatment with anti-leukotrienes was needed in one patient. Associated thyroiditis was diagnosed in one patient, which was controlled with levothyroxine. CONCLUSIONS: Pediatric CU showed features similar to CU in adulthood, including a greater predominance in females and frequent association with personal or family history of atopy. Adult guidelines for the treatment of CU are currently extrapolated to the pediatric population. Specific tools for the assessment of disease activity and impairment of quality of life in pediatric CU are needed for use in prospective studies aimed to define treatment strategies for children with CU.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (27)
- doi:10.1016/j.ad.2016.12.012 via openalex
- doi:10.1136/adc.88.6.517 via openalex
- doi:10.1111/all.13397 via openalex
- doi:10.1111/j.1399-3038.2005.00309.x via openalex
- doi:10.1016/j.jaad.2014.05.069 via openalex
- doi:10.1016/j.jaci.2014.02.036 via openalex
- doi:10.1186/s13052-019-0695-x via openalex
- doi:10.3345/kjp.2015.58.5.159 via openalex
- doi:10.1111/pai.12967 via openalex
- doi:10.1186/s13601-017-0141-3 via openalex
- W218182151 via openalex
- doi:10.1007/s11882-018-0787-5 via openalex
- doi:10.1111/j.1399-3038.2010.01120.x via openalex
- doi:10.2500/aap.2016.37.4010 via openalex
- doi:10.1111/jdv.13697 via openalex
- doi:10.1111/pde.14360 via openalex
- doi:10.5152/turkpediatriars.2016.4042 via openalex
- doi:10.1016/j.jaip.2018.02.015 via openalex
- doi:10.1016/j.anai.2019.05.003 via openalex
- doi:10.1001/jamadermatol.2017.3182 via openalex
- doi:10.1111/pai.12407 via openalex
- doi:10.1111/all.12313 via openalex
- doi:10.1111/jdv.15045 via openalex
- doi:10.2340/00015555-1573 via openalex
- doi:10.1684/ejd.2013.2158 via openalex
- doi:10.1016/j.jaad.2018.01.023 via openalex
- doi:10.1111/pai.12609 via openalex
SciLite annotations
chemicals 2
tocilizumab
leukotriene
Source provenance
- openalex
- last seen: 2026-05-10T11:25:14.011203+00:00
- scilite
- last seen: 2026-05-18T04:26:01.642840+00:00
License: CC0
· commercial use OK